DDR1 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
This Target Evaluation Report for DDR1 is generated from PatSnap Life Sciences MCP data workflows, combining Target & Disease MCP biology context with Clinical Trials MCP validation and competitive signals.
For AI teams building biomedical agents, PatSnap Life Sciences MCP Servers provide structured retrieval across target biology, disease context, clinical trials, drug evidence, IP intelligence, and other R&D intelligence sources.
55 Direct drug records from Target & Disease MCP | 50 Development records in target context | 108 Disease associations captured | 252 Clinical trial records from Clinical Trials MCP |
Explore PatSnap Life Sciences MCP Servers for AI agents
Executive View
DDR1 connects collagen sensing with invasion and matrix remodeling
Target & Disease MCP profiles DDR1 as a fibrillar-collagen receptor tyrosine kinase that regulates extracellular-matrix attachment, remodeling, migration, differentiation, survival, proliferation, wound healing, mammary-gland differentiation, hearing biology, smooth-muscle migration, tumor invasion, SRC/MAPK signaling, PTPN11, and MMP2/MMP7/MMP9 induction.
Evidence is focused and matrix-biology driven
The MCP workflow retrieved 55 direct drug records, 50 development records, and 108 disease associations. Clinical Trials MCP returned 252 records. DDR1 is a niche but interesting target where fibrosis, invasion, and stromal biology can differentiate a program.
Clinical competition includes kinase overlap
Recent trial examples include C019199 versus gemcitabine/docetaxel in osteosarcoma, nilotinib bioequivalence, and asciminib maintenance after allo-HSCT. These are directional kinase-landscape signals, not all DDR1-selective programs.
IP and strategy view
DDR1 IP should focus on collagen-rich tumor microenvironments, fibrosis indications, invasion biomarkers, and selectivity versus other kinases.
Clinical Validation and Competitive Landscape
Clinical Trials MCP returned 252 registered trial records connected to DDR1. The sample below is used as a directional competitive readout rather than a full regulatory review.
| Trial | Phase | Status |
|---|---|---|
| C019199 versus gemcitabine plus docetaxel in osteosarcoma after second-line failure | Phase 3 | Not yet recruiting |
| Nilotinib capsule bioequivalence study | Not Applicable | Not yet recruiting |
| Asciminib maintenance after allo-HSCT in Ph+ B-ALL or blast-transformed CML | Phase 2 | Not yet recruiting |
R&D Strategy Recommendation
DDR1 is worth advancing when matrix biology is central to the disease hypothesis. A broad kinase approach should be avoided without fibrosis, stromal, or invasion-linked patient selection.
Start building target evaluation agents with PatSnap Life Sciences MCP Servers
